The issue of aging is SO IMPORTANT in the field of rheumatology, and it's not only relevant to drug trials. For example, up to 20% of SLE patients are "late-onset" (diagnosed after age 50). These patients are being under-diagnosed and under-treated because they don't fit the expected SLE profile, and they are being virtually excluded from the SLE conversation in most rheumatology trainings and podcasts. I applaud the authors for shining a light on inclusion of older patients in clinical trials! Perhaps this kind of systematic review and analysis will begin to expose the enormous chasm that exists between rarified clinical criteria and trials and real-world patients. Real patients come in all colors, sizes and ages. Yes, such inclusion presents many challenges, but it has to be done. It's our job. Thanks for this work and for the courage it takes to expose an issue that has been hiding in plain sight!